Abstract
Extreme disease phenotypes have the potential to provide key pathophysiologic insights, but the study of these conditions is challenging due to their rarity and the limited statistical power of existing methods. Herein, we apply a novel pathway-based approach to investigate the role of rare genomic variants in infectious purpura fulminans (PF)1,2, an extreme phenotype of sepsis with hyperinflammation and coagulopathy for which the role of inherited risk factors is currently unknown. Using whole exome sequencing, we found a significantly increased burden of rare, putatively function-altering coding variants in the complement system in patients with PF compared to unselected patients with sepsis (p-value = 0.01). Functional characterization of a subset of PF-associated variants in integrin complement receptors 3 and 4 (CR3 and CR4) revealed that they exhibit a pro-inflammatory phenotype. Our results suggest that rare inherited defects in the complement system predispose individuals to the maladaptive hyperinflammatory response that characterizes severe sepsis.
Competing Interest Statement
J.-A. Losman has received funding support unrelated to this project via DFCI from Lilly and via the Broad Institute from Bayer. S.S. is an associate member at the Broad Institute. He serves as a consultant and a member of the genetics advisory board at NGM Biopharmaceuticals and a consultant at Inari Agriculture.
Funding Statement
P.K.B. was supported by Beth Israel Deaconess Medical Center and the National Institutes of Health (R21 HL153655 and K08 HL136840). S.N. gratefully acknowledges support from the Australian Parkinson's Mission through funding from the Australian government. J.A.L. was supported by the Dana Farber Cancer Institute.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Institutional Review Boards of Partners Healthcare and Beth Israel Deaconess Medical Center provided ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Raw whole-exome sequencing data from PF patients will be available upon request. Raw whole-exome sequencing data from unselected sepsis patients is available from the NHLBI ARDSnet iSPAAR consortium (dbGaP Study Accession: phs000631.v1.p1). The variant call file containing the jointly-called sequence variants passing GATK filters that were analyzed in this paper will be available through dbGaP. The source code for RVTT is available through https://github.com/snz20/RVTT. Source data for all figures and tables are provided with the manuscript.
https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/molecular.cgi?study_id=phs000631.v1.p1
